Yes. My first question is, is Granules planning to participate in the GL -1 market, given it's growing significance in the pharmaceutical landscape?
Okay. Thank you for the update. My next question is, with the finished dosages contributing 76% of revenues, what is the outlook for this segment? And are there plans to diversify revenue streams further?